Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 7/20 | 0.49 |
| ▸ | PDE2A | O00408 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442757 | 0.86 | ADORA2A (0.36) | ADAPDE2ACYP3A4PDE4APDE4B | |
| SCHEMBL6051984 | 0.85 | HPGD (0.42) | PDE2AALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL7449080 | 0.85 | ADORA2A (0.39) | ALDH1A1CYP1A2ALOX15TSHRHIF1A | |
| SCHEMBL7442592 | 0.83 | HPGD (0.38) | ADAPDE2AALDH1A1ALOX15TSHR | |
| SCHEMBL6051952 | 0.76 | ADA (0.51) | ADAPDE2ACYP3A4PDE4APDE4B | |
| Nosantine SCHEMBL2111679 | 0.75 | ADA (0.65) | ADAPDE2ACYP3A4PDE4APDE4B | |
| SCHEMBL7433401 | 0.74 | ALDH1A1 (0.40) | PDE2AALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL7445158 | 0.73 | ALDH1A1 (0.40) | PDE2AALDH1A1ALOX15HSD17B10TSHR | |
| SCHEMBL8140677 | 0.72 | PDE5A (0.60) | ADAPDE2APDE4APDE4BPDE4C | |
| SCHEMBL25095261 | 0.71 | ADORA2A (0.49) | CYP3A4CYP1A2SMN1; SMN2TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6440981-B1 | REGULATING APOPTOSIS IN HUMAN CELLS COMPRISING EXPOSING SAID CELLS TO AN EFFECTIVE AMOUNT OF A 2,9-DISUBSTITUTED PURINE-6 ONE COMPOUND | CELL PATHWAYS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020032209-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones | OSI PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
| US-6268372-B1 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones | CELL PATHWAYS, INC. | 2001-07-31 | — | — | US | disclosed |
| US-5861404-A | ANTIINFLAMMATORY AGENTS, THROMBOEMBOLIC AND CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-19 | — | — | US | disclosed |
| EP-0722944-A1 | 2-9-Disubstituted Purin-6-ones | BAYER AG (DE) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032209-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones | MKI67, PCNA, HRAS | ADA 3473/4885PDE2A 4184/4885CYP3A4 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.